3H Medi Solution (formerly CROee INC), Japan, in furtherance with its organizational goals, recently had table talks with its prospective associate, Keio University Hospital, represented by Dr. Kenzo Soejima (MD Ph.D.), Director of Clinical and Translational Research Center at the University, wherein Dr. Soejima spoke about the ongoing activities and forward trends in Clinical Trials, Patient Recruitments, Research and Bio Ventures. Here is the excerpt of 3H Medical Solution’s takeaway from the discussions:

3H Medi Solution perceives its prospective associate Keio University Hospital as not only a clinical research hospital, but also as a potential base for promoting venture businesses and creating the relevant support systems. However, currently, since there are very few tangible promotional ideas particularly for local ventures, in addition to having an incapacity to connect and conduct substantial activities, 3H Medi Solution aims to deliver the prospects of development and support of promotional ideas and solutions even from venture businesses across the globe.

3H Medi Solution further foresees a cooperation for development from the academia associated with MARC, the Metropolitan Academic Research Consortium within Tokyo, which has been set up around the activities of Keio University Hospital. The Consortium has a flagship membership of 19 medical institutions alone from the private medical schools of the Tokyo Metropolitan Area.   

After further discussion with Dr. Soejima, 3H Medi Solution positively speculates the fast recruitments of patients even with rare disease and cancer, owing to the vast bed capacities of the MARC facilities, which is a whopping total of One Hundred and Ninety Thousand (190000) beds.

3H Medi Solution also attributes Dr. Soejima’s positive outlook in this matter to the fact that Keio University has numerous PMDA consultation experiences within domains such as Regenerative medicine under its belt. 3H Medi Solution has placed its confidence in the University Hospital to achieve a highly advantageous position under the circumstances if the Bio ventures of Regenerative medicines make progress within Japan.   Moreover 3H Medi Solution supports Dr. Soejima’s strong belief that the key strengths of the University Hospital lie in the fields of Regenerative Medicines, Cancer and Immunity.

Furthermore, 3H Medi Solution is also privy to the thought process working behind Keio University Hospital regarding the licenses and Intellectual Property related to the development and support of the Bio Ventures. In furtherance, 3H Medi Solution invites Ventures from across the globe for fundamental business discussions with the University Hospital based on the following key points, wherein the University Hospital’s clinical research data shall be propositioned as an intellectual property to the Bio Ventures, and after assessing the data value, there may also be a possibility of carrying out certain requisite restorations.

In conclusion, 3H Medi Solution is highly confident regarding the maneuvers of Keio University Hospital under the guidance of Dr. Soejima, wherein there is specifically a positive estimation regarding the success of their clinical trials owing to the service capacity of the MARC facilities. 3H Medi Solution also looks forward to mediating in creation of work association of the University Hospital with international Bio ventures since 3H Medi Solution strongly endorses the advanced experience and knowledge base of the Keio University Hospital in the domains of cancer, immunity etc. and thereby encourages international ventures to initiate positive business dialogues to benefit from the prospective success of these Bio Ventures.

For any further queries regarding this article please feel free to contact imran@3h-ms.co.jp